Skip to content
Dr Micaela Gal

Dr Micaela Gal

Institutional Translational Manager

School of Biosciences

Email:
galm@cardiff.ac.uk
Location:
Medicines Discovery Institute, Main Office, Main Building, Park Place, Cardiff, CF10 3AT

 I am the 'Institutional Translation Manager' at Cardiff University, funded by a Wellcome Trust ‘Institutional Translation Partnership Award' (since July 2019). My role includes assessing the translational research landscape within Cardiff University and supporting researchers by providing training, assistance and advice on translational research applications and activities. I work across the University and am based at both the Medicines Discovery Institute and the Research and Innovation Services (RIS) Commercial Division for part of each week.

From 2017 to 2019, I was Knowledge Mobilisation and Impact Manager of the Health and Care Research Wales funded 'Primary and Emergency Care Research (PRIME) Centre Wales based at the School of Medicine, Cardiff University. I was also Impact Lead for the Division of Population Medicine. In these roles I specialised in engagement, developing stakeholder collaborations, communication and implementation of research findings to ensure research evidence had the best chance of being accessed, used and implemented to make a real world difference (impact).

I joined the School of Medicine, Cardiff University in 2009 as a Research Fellow specialising in ‘Portfolio Development’ and delivery of research within PRIME Centre Wales and the Wales School of Primary Care Research. For the next 8 years, my role included preparation of large, high-value funding applications, project management and conducting research. The research I was involved in included large cross-European clinical trials of interventions in primary care that aimed to reduce antimicrobial resistance, development of novel diagnostics for infectious diseases and identifying barriers and solutions to the set up and conduct of clinical trials in infectious disease outbreaks and pandemics across Europe. Projects funders included WG Health and Care Research Wales, EU FP7, EU Innovative Medicines Initiative (IMI) (working with Pharma EFPIA partners and SMEs), National Institute of Health Research (NIHR) Health Technology Assessment (HTA) and Efficacy and Mechanisms Evaluations (EME). During this time I gained extensive experience of clinical trials set-up and conduct, developing target product profiles, quantitative and qualitative research methodologies and process evaluations.

After graduating with a Microbiology BSc from Cardiff University and DPhil from St Hilda’s College, Oxford University (Molecular Microbiology), I joined the NHS in 1999. Over the next 10 years, I gained my Health and Care Professions (HCPC) ‘Clinical Scientist’ registration and worked in two specialist National Reference Laboratories (Anaerobe Reference Laboratory, Public Health Wales and the Antimicrobial Chemotherapy Laboratory, Bristol NHS Trust). Here I set up and led molecular diagnostic services specialising in the development, implementation and evaluation of new diagnostic tests and services for rapid molecular diagnosis of anaerobic infections, hospital acquired infections, antimicrobial resistance and Tuberculosis. I also worked extensively on C. difficile ribotyping.

I have also taught and supervised numerous students, given lectures, and led and participated in public engagement events representing Cardiff University events at the National Eisteddfod 2017 ('Bugs: the good, the bad and the ugly') and Techniquest 2018 ('Superbugs').

2019

2018

2017

2016

2015

2014

2013

2012

2006

2005

2004

2003

Research Intersts: Translational research (from bench to bedside). knowledge mobilisation, research impact, stakeholder engagement, clinical trials, research grant development.

Experience includes the above and qualitative and quanitative research methods, trials set-up and conduct, consensus setting, process evaluations.

GRANTS:

  • Wales Primary and Emergency Care Research (PRIME) Centre; Application to Welsh Government Health and Care Research Wales, Infrastructure Funding. Total value £5m, April 2019, Co-applicant. Decision pending;
  • KESS PhD Studentship: Bee Well Caerphilly (Second supervisor). Application with CU School of Pharmacy and Aneurin Bevan Health Board. Start: Autumn 2017. Co-applicant;
  • PREPARE: Platform for European Preparedness Against (Re-) emerging Epidemics. Funder: EU FP7. Total Value £24m. Start: 2014. Co-applicant
  • General practitioner use of a C-reactive protein point of care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (The PACE Study). Funder NIHR HTA. Total Value £1.2m. Start 2015. Co-applicant
  • The Missing Link study. Symptoms of uncomplicated urinary tract infection (UTI) in women presenting to General Practice: Explorations of causation in culture negative urines. Funder: WSPCR. Total Value £22,384. Start: 2015. Co-applicant
  • Natural salicylates in fruit and vegetables and the prevention of human cancer. Funder: WSPCR. Total Value £22,000. Start: 2015. Co-applicant
  • PRINCESS: Probiotics to Reduce Infections iN CarE home Service userS. Funder: NIHR Efficacy and Mechanism Evaluation (EME) Programme. Total value £2.4m. Start: 2014. Co-applicant.General Practitioner (GP) use of a C-Reactive Protein (CRP) Point of Care Test (POCT) to help target antibiotic prescribing to patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) who are most likely to benefit (The PACE Study). Funder: NIHR HTA. Total Value £1.3m. Start: 2014. Co-applicant
  • RAPP-ID; Development of RApid Point-of-Care test Platform for Infectious Diseases. Funder: EU Innovative Medicines Initiative (IMI). Total value: £12m. Start: 2011. Co-applicant
  • R-GNOSIS: Resistance in Gram-Negative Organisms: Studying Intervention Strategies. Funder: EU FP7. Total value: £9m. Start: 2011. Co-applicant
  • OSTRICH: Oral Steroids for Resolution of Otitis Media with Effusion (OME) In Children. Funder: NIHR HTA. Total value: £1,220,332. Start: 2012. Co-applicant
  • Population Surveillance of Panton-Valentine Leukocidin-positive S. aureus and Community-Associated MRSA in South West England. Funder: Department of Health. Total value: £46,088. Start: 2008. Co-PI
  • Sentinel and Population Surveillance of Panton-Valentine Leukocidin-positive Staphylococcus aureus and Community-Associated MRSA in the UK. Funder: Department of Health. Total value: £139,859. Start Date: December 2007. Co-PI

OTHER ACTIVITIES

  • Winner of the Cardiff University, School of Medicine STAR award: Dean of Research Excellence Award (April 2019)
  • Member of the Division of Population Medicine (DPM) ‘Equality, Diversity and Inclusion’ board and Athena Swan panel (until June 2019);
  • Member of the DPM Innovation, Impact and Engagement Team (Co-lead until June 2019);
  • Division of Population Medicine Impact lead for REF 2021 (until June 2019);
  • Wellbeing initiatives for staff, 2019, workshops and wellbeing garden set-up (until June 2019).

Engagement with stakeholders have included industry, Welsh Government, National Assembly Wales Research service, Health and Care Research Wales, third sector, social care, academics, NHS, public health.

Public and patient engagement: including conducting interviews, focus groups, public panels, interactive events at National Eisteddfod and Techniquest

External profiles